Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adapalene + benzoyl peroxide is a fixed-dose **topical combination** acne therapy composed of adapalene, a third-generation retinoid, and benzoyl peroxide, an oxidizing antimicrobial and keratolytic agent. It is marketed as gels including **Epiduo** and **Epiduo Forte** and is indicated for the topical treatment of **acne vulgaris**. The combination is designed to address complementary pathogenic drivers of acne: adapalene modulates retinoid-responsive pathways that normalize follicular keratinization and reduce inflammatory signaling, while benzoyl peroxide exerts bactericidal activity against *Cutibacterium acnes* and helps reduce comedones and inflammatory lesions. Public sources including FDA labeling, DailyMed listings, and ClinicalTrials.gov records verify the product and its development and marketed use in acne vulgaris.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adapalene + benzoyl peroxide.